0.80
+0.0299(+3.88%)
Currency In USD
| Previous Close | 0.77 |
| Open | 0.81 |
| Day High | 0.82 |
| Day Low | 0.76 |
| 52-Week High | 3.15 |
| 52-Week Low | 0.57 |
| Volume | 112,960 |
| Average Volume | 199,912 |
| Market Cap | 13,044 |
| PE | -0.31 |
| EPS | -2.58 |
| Moving Average 50 Days | 0.9 |
| Moving Average 200 Days | 1.12 |
| Change | 0.03 |
If you invested $1000 in Akari Therapeutics, Plc (AKTX) 10 years ago, it would be worth $2.16 as of October 19, 2025 at a share price of $0.8. Whereas If you bought $1000 worth of Akari Therapeutics, Plc (AKTX) shares 5 years ago, it would be worth $23.25 as of October 19, 2025 at a share price of $0.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
GlobeNewswire Inc.
Oct 15, 2025 12:30 PM GMT
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a defi
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
GlobeNewswire Inc.
Oct 09, 2025 12:45 PM GMT
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has filed two new provisional patent ap
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
GlobeNewswire Inc.
Oct 03, 2025 1:30 PM GMT
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced its abstract has been accepted for oral present